Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Rainer Claus, MD, Gabriele Ihorst, PhD, Philipp Sander, Ljudmila Bogatyreva, Heiko Becker, MD, Pierre W Wijermans, MD, Stefan Suciu, Emmanuel Bissé, MD PhD, Michael Lübbert, MD

Blood (2016) 128 (22): 3175.

https://doi.org/10.1182/blood.V128.22.3175.3175

Published: 2016

Journal Articles

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

Benjamin Kasenda, MD PhD, Gabriele Ihorst, PhD, Heidi Fricker, Elke Valk, PhD, Elisabeth Schorb, MD, Kristina Fritsch, MD, Jürgen Finke, Gerald Illerhaus, MD

Blood (2016) 128 (22): 5385.

https://doi.org/10.1182/blood.V128.22.5385.5385

Published: 2016

Journal Articles

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Maximilian Schinke, Inga Promny, MD, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Roland H. Mertelsmann, MD PhD, Justus Duyster, MD, Ralph M. Waesch, MD, Martin Schumacher, PhD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5953.

https://doi.org/10.1182/blood.V128.22.5953.5953

Published: 2016

Journal Articles

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Sophia Scheubeck, Sandra Maria Dold, M. Sc., Gabriele Ihorst, PhD, Alexander Zober, MD, Stefan J. Müller, Dipl.-Pharm., Christian Langer, MD, Wolfram Pönisch, Lars-Olof Mügge, MD, Stefan Knop, MD, Justus Duyster, MD, Martin Schumacher, PhD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5627.

https://doi.org/10.1182/blood.V128.22.5627.5627

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

Journal Articles

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Blood (2016) 128 (22): 781.

https://doi.org/10.1182/blood.V128.22.781.781

Published: 2016

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

Journal Articles

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Salem Ajib, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Livius Penter, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, Michael Luebbert, MD, Ralph M. Waesch, MD PhD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Robert Negrin, MD, Mats L Brune, Alexandros Spyridonidis, Annette Schmitt-Graeff, MD, Walter van der Velden, MD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MDPhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Joerg Halter, MD, Gerard Socie, Dietrich Beelen, MD, Christian Peschel, MD, Andreas Neubauer, MD, Juergen Finke, MD, Justus Duyster, MD PhD, Nikolas von Bubnoff, MD

Blood (2015) 126 (23): 858.

https://doi.org/10.1182/blood.V126.23.858.858

Published: 2015

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Alexander Zober, MD, Mandy Möller, Sandra-Maria Dold, Gabriele Ihorst, PhD, Stefanie Hieke, PhD, Jochen Knaus, Milena Pantic, PhD, Barbara Deschler-Baier, MD, Stefan Knop, Hermann Einsele, Christian Langer, Lars-Olof Muegge, MD, Wolfram Poenisch, MD, Justus Duyster, MD PhD, Martin Schumacher, PhD, Ralph M. Waesch, MD PhD, Monika Engelhardt, MD PhD

Blood (2015) 126 (23): 5616.

https://doi.org/10.1182/blood.V126.23.5616.5616

Published: 2015

Journal Articles

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Maximilian Schinke, Inga Promny, MD, Stefanie Hieke, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, PhD, Milena Pantic, PhD, Justus Duyster, MD, Ralph Wäsch, MD PhD, Martin Schuhmacher, PhD, Monika Engelhardt, MD

Blood (2015) 126 (23): 2091.

https://doi.org/10.1182/blood.V126.23.2091.2091

Published: 2015

Journal Articles

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Martina Kleber, MD, Gabriele Ihorst, PhD, Christian Jakob, MD, Peter Liebisch, MD, Bernd Koch, PhD, Monika Engelhardt, MD

Blood (2007) 110 (11): 4830.

https://doi.org/10.1182/blood.V110.11.4830.4830

Published: 2007

Journal Articles

Bone Marrow Hypocellularity, Decreased Platelet Counts and Colony Forming Units Serve as Prognostics Parameters for Early Events after Auto-Peripheral Blood Stem Cell Transplantation.

Antonia M.S. Mueller, MD, Gabriele Ihorst, PhD, Peter S. Haas, MD, Dagmar Wider, Monika Engelhardt, MD

Blood (2006) 108 (11): 5448.

https://doi.org/10.1182/blood.V108.11.5448.5448

Published: 2006

Journal Articles

Bone Marrow Hypocellularity, Decreased Platelet Counts and Colony Forming Units Serve as Prognostics Parameters for Early Complications after Autologous Peripheral Blood Stem Cell Transplantation.

Antonia M.S. Mueller, MD, Gabriele Ihorst, PhD, Denz Ulrich, MD, Doeing Carsten, Wider Dagmar, Engelhardt Monika, MD

Blood (2005) 106 (11): 5514.

https://doi.org/10.1182/blood.V106.11.5514.5514

Published: 2005

Journal Articles

Serum Free Light Chain (FLC) Measurement in Multiple Myeloma (MM) Patients (pts) Correlate with Known Monoclonal Paraprotein, Disease Stage and Therapy Response.

Monika Engelhardt, MD, Daniel Räpple, MD, Andreas Weis, MD, Emanuel Bisse, MD, Gabriele Ihorst, PhD

Blood (2004) 104 (11): 4907.

https://doi.org/10.1182/blood.V104.11.4907.4907

Published: 2004

Journal Articles

A Single Center Analysis over a Ten Year Period on Transplant Related Mortality (TRM), Early Relapse (ER) and Failure of Blood Cell Reconstitution (FBR) in High-Risk (HR) Cancer Patients (PTS) Undergoing Autologous PBSCT (auto-PBSCT): Frequency, Outcome and Prognostics.

Monika Engelhardt, MD, Carsten Doeing, Gabriele Ihorst, PhD, Dagmar Wider, Juergen Finke, MD

Blood (2004) 104 (11): 5199.

https://doi.org/10.1182/blood.V104.11.5199.5199

Published: 2004

NARROW

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Bone Marrow Hypocellularity, Decreased Platelet Counts and Colony Forming Units Serve as Prognostics Parameters for Early Events after Auto-Peripheral Blood Stem Cell Transplantation.

Bone Marrow Hypocellularity, Decreased Platelet Counts and Colony Forming Units Serve as Prognostics Parameters for Early Complications after Autologous Peripheral Blood Stem Cell Transplantation.

Serum Free Light Chain (FLC) Measurement in Multiple Myeloma (MM) Patients (pts) Correlate with Known Monoclonal Paraprotein, Disease Stage and Therapy Response.

A Single Center Analysis over a Ten Year Period on Transplant Related Mortality (TRM), Early Relapse (ER) and Failure of Blood Cell Reconstitution (FBR) in High-Risk (HR) Cancer Patients (PTS) Undergoing Autologous PBSCT (auto-PBSCT): Frequency, Outcome and Prognostics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only